Related references
Note: Only part of the references are listed.Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
Pasi A. Janne et al.
CANCER DISCOVERY (2022)
Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
Tianqi Xu et al.
CANCERS (2021)
PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology
Sara S. Rinne et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
Sara S. Rinne et al.
CANCERS (2021)
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
Wen Yin et al.
PHARMACEUTICS (2021)
Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
Haozhong Ding et al.
PHARMACEUTICS (2021)
Antibody-Drug Conjugates: A Comprehensive Review
Puregmaa Khongorzul et al.
MOLECULAR CANCER RESEARCH (2020)
Engineered Protein Scaffolds as Next-Generation Therapeutics
Michaela Gebauer et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours
Pieterjan Debie et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules
Sara S. Rinne et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
Gavin Bennett et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
Charles Dahlsson Leitao et al.
PHARMACEUTICS (2020)
Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life
Fabian Brandl et al.
JOURNAL OF CONTROLLED RELEASE (2020)
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
J. Laskin et al.
ANNALS OF ONCOLOGY (2020)
Antibody-Drug Conjugates: The Last Decade
Nicolas Joubert et al.
PHARMACEUTICALS (2020)
Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers
Charles Dahlsson Leitao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARP in G3
Anzhelika Vorobyeva et al.
SCIENTIFIC REPORTS (2019)
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
Yuuri Hashimoto et al.
CLINICAL CANCER RESEARCH (2019)
Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates
Haozhong Ding et al.
CANCERS (2019)
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Anna Wolska-Washer et al.
DRUG SAFETY (2019)
Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors
Mohamed Altai et al.
JOURNAL OF CONTROLLED RELEASE (2018)
HER3 signaling and targeted therapy in cancer
Rosalin Mishra et al.
ONCOLOGY REVIEWS (2018)
Affibody Molecules in Biotechnological and Medical Applications
Stefan Stahl et al.
TRENDS IN BIOTECHNOLOGY (2017)
Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
Katerina T. Xenaki et al.
FRONTIERS IN IMMUNOLOGY (2017)
Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors
Chiara Da Pieve et al.
BIOCONJUGATE CHEMISTRY (2016)
Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
Aino Salmiheimo et al.
PLOS ONE (2016)
Affibody-mediated PET imaging of HER3 expression in malignant tumours
Maria Rosestedt et al.
SCIENTIFIC REPORTS (2015)
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome
Jill M. Siegfried et al.
NEOPLASIA (2015)
Site-Specific Photoconjugation of Antibodies Using Chemically Synthesized IgG-Binding Domains
Anna Perols et al.
BIOCONJUGATE CHEMISTRY (2014)
Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule
Anna Orlova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
Allan Lipton et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [99mTc(CO)3]+-Labeled Affibody Molecules
Camilla Hofstrom et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Correction: Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
Magdalena Malm et al.
PLoS One (2013)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Use of a HEHEHE Purification Tag Instead of a Hexahistidine Tag Improves Biodistribution of Affibody Molecules Site-Specifically Labeled with 99mTc, 111In and 125I
Camilla Hofstrom et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules
Nina Kronqvist et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [99mTc(CO)3]+, and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation
Vladimir Tolmachev et al.
BIOCONJUGATE CHEMISTRY (2010)
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
J. Spencer Liles et al.
CANCER BIOLOGY & THERAPY (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
J. Lofblom et al.
FEBS LETTERS (2010)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
M. K. Robinson et al.
BRITISH JOURNAL OF CANCER (2008)
HER3 is a determinant for poor prognosis in melanoma
Markus Reschke et al.
CLINICAL CANCER RESEARCH (2008)
Engineering of a femtomolar affinity binding protein to human serum albumin
Andreas Jonsson et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2008)
Factors determining antibody distribution in tumors
Greg M. Thurber et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Expression and nuclear localization of ErbB3 in prostate cancer
IH Koumakpayi et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
